The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Cabozantinib plus pembrolizumab as first-line therapy for cisplatin-ineligible advanced urothelial carcinoma (PemCab).
 
Rohit K. Jain
Honoraria - Curio Science; DAVA Oncology; FLASCO; MJH Life Sciences
Consulting or Advisory Role - AVEO; Bristol-Myers Squibb; EMD Serono; Gilead Sciences; Sanofi
Speakers' Bureau - Seattle Genetics/Astellas
Research Funding - Bristol Myers Squibb; Gilead Sciences; NCI
Travel, Accommodations, Expenses - DAVA Oncology; FLASCO; Sanofi
 
Umang Swami
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Exelixis; Imvax; Pfizer; Sanofi; Seagen
Research Funding - Exelixis (Inst); Janssen (Inst); Seattle Genetics/Astellas (Inst)
 
Mehmet Asim Bilen
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Calithera Biosciences; Eisai; EMD Serono; Exelixis; Exelixis; Genomic Health; Janssen; Nektar; Pfizer; Sanofi; SeaGen
Research Funding - Advanced Accelerator Applications (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Genentech/Roche (Inst); Genome & Company (Inst); Incyte (Inst); Merck (Inst); Nektar (Inst); NiKang Therapeutics (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Seagen (Inst); Tricon Pharmaceuticals (Inst); Xencor (Inst)
 
Kenneth M. Boucher
No Relationships to Disclose
 
Jacqueline T Brown
Honoraria - Curio/Vaniam Group
Research Funding - Medicenna (Inst); Surface Oncology (Inst); Xencor (Inst)
Travel, Accommodations, Expenses - Curio/Vaniam Group
 
Jad Chahoud
Consulting or Advisory Role - AVEO; DAVA Pharmaceuticals; Exelixis; Pfizer
 
Sumati Gupta
Stock and Other Ownership Interests - Salarius Pharmaceuticals (I)
Research Funding - Acrotech Biopharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Daiichi Sankyo/Lilly (Inst); Five Prime Therapeutics (Inst); Hoosier Cancer Research Network (Inst); Immunocore (Inst); Incyte (Inst); LSK BioPharma (Inst); MedImmune (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); QED Therapeutics (Inst); Rexahn Pharmaceuticals (Inst); Seagen (Inst); Viralytics (Inst)
Travel, Accommodations, Expenses - QED Therapeutics
(OPTIONAL) Uncompensated Relationships - Astellas Pharma
 
Neeraj Agarwal
Research Funding - Amgen (Inst); Arvinas (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celldex (Inst); crispr therapeutics (Inst); Eisai (Inst); Exelixis (Inst); Genentech (Inst); Gilead Sciences (Inst); Immunomedics (Inst); Janssen (Inst); Lilly (Inst); Merck (Inst); Nektar (Inst); ORIC Pharmaceuticals (Inst); ORIC Pharmaceuticals (Inst); Pfizer (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Exelixis; Pfizer
 
Guru P. Sonpavde
Employment - Myriad Genetics (I)
Honoraria - UpToDate
Consulting or Advisory Role - Astellas Pharma; Bicycle Therapeutics; Bristol-Myers Squibb; EMD Serono; Exelixis; G1 Therapeutics; Genentech; Gilead Sciences; Infinity Pharmaceuticals; Janssen; Loxo/Lilly; Lucence; Merck; Pfizer; Scholar Rock; Seagen; Syapse; Vial
Speakers' Bureau - Exelixis; Gilead Sciences; INFORMAÇÃO BRASILEIRA DE ONCOLOGIA; Medscape; Natera; Onclive; Physicans' Education Resource; Research to Practice; Seagen
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); GeneCentric (Inst); Gilead Sciences (Inst); Jazz Pharmaceuticals (Inst); Predicine (Inst); QED Therapeutics (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb
Other Relationship - Astellas Pharma; Bristol-Myers Squibb; Elsevier; G1 Therapeutics; Mereo BioPharma; QED Therapeutics
 
Benjamin L. Maughan
Consulting or Advisory Role - Astellas Medivation; AVEO; Bavarian Nordic; Bayer; Bristol-Myers Squibb; Clovis Oncology; Exelixis; Janssen Oncology; Merck; Peloton Therapeutics; Pfizer; Tempus
Research Funding - Bavarian Nordic (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Exelixis (Inst)
Travel, Accommodations, Expenses - Exelixis